An Application Of Multivariate Analysis To Some Tranquilzer Comparison Experiments by Van Eeden, Constance et al.
* 
November 1963 
AN APPLICATION OF MULTIVARIATE ANALYSIS TO SOME 
* TRANQUILIZER COMPARISON EXPERIMENTS 
Constance van Eeden, Gordon T. Reistad and Charles H. Kraft 
Technical Report No. 32 
University of Minnes»ta 
Minneapolis, Minnesota 
This research was supported in part under Grant Number 2G-43(c7+8) 
of the National Institutes of Health, under Grant Number MYP-51O6 of the 
National Institute of Mental Health, U. s. Public Health Service and 
under Grant Number Nonr JlO(31) of the Office of Naval Research. 
--
-
AN APPLICATION OF MULTIVARIATE ANALYSIS TO SOME 
TRANQUILIZER COMPARISON EXPERIMENTS 
by 
Constance van Eeden, l) Gordon T. Heistad2) and·.\charles H. Kraft3) 
1. Introduction 
Two groups of patients were rated by the Wittenborn psychiatric rating 
scale before and after treatment. Group I, 16 patients, were administered the 
tranquilizer thioridazine (Mellaril), Group II, 17 patients, were administered 
the tranquilizer carphenazine (Proketazine). The Wittenborn psychiatric rating 
scale is an instrument which was designed to detect the severity of symptoms in 
each of nine areas, which we will call sub-scales; they are in fact symptom 
clusters derived on the basis of a factor analysis done by Wittenborn on a rather 
different population than that used in this study [3]. 
To test whether there is any difference between the two treatments, the 
changes in the Wittenborn sub-scales (pre-treatment minus post-treatment) were 
computed. It was assumed that these changes were, for the patients in each 
group, independent observations from multivariate normal populations. It was 
further assumed that the changes in one group were independent of those in the 
other group and that the population: ·covariance: matrices were the same for the two 
groups, Under these assumptions a difference between the treatments would appear 
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as a difference between the means. 
The appropriate test that this difference is zero is Hotelling's T2 
[1, pp. 108-109]. This test is the analogue of Student's t for the univariate 
case and is a distance between the group (vector) means. The mean for each 
group defines a point in 9-dimensional space, each dimension being a sub-scale 
of the Wittenborn. If the distance between these points is large, in units 
defined by the estimated covariance matrix, Hotelling's T2 will be large and 
the test will reject the hypothesis of no treatment difference. 
It is important to note that this distance can be large in many ways. For 
instance one drug might produce relative changes in the sub-scales of the 
Wittenborn which are the same as those for the second drug but greater in 
magnitude. That is the vectors of means would have the same direction but 
different lengths. On the other hand it could be that the magnitude of change 
is about the same for the two drugs but that one drug produces changes on a 
different set of sub-scales than does the other drug. That is the two vectors 
of means have different directions. 
In the first case it could be said that one drug is more effective than the 
other, but they each affect the same symptoms. In the second case the drugs 
could be said to be equally effective (over-all) but that they affect different 
symptoms. Of course the difference might not clearly be one or the other of 
these. 
2. Results 
The data are given on page 10 for drug I and on page 11 for drug II. The 
observed means and covariance matrices for each of the two groups are given on 
page 12. These means are graphed in Figure 1 and the observed mean difference 
between the two groups (Group I minus Group II) is tabled, with the combined 
covariance matrix, in Table 1. 
-2-
mean 
1.5 
1.0 
.5 
0 2 
' 
' 
' 
' o---X 
I I J 
.,, 
x Drug I 
o Drug II 
/~ 
/ \ 
/" \ 
"/ 8 \ 
Figure 1: Observed means for Drug I and Drug II. 
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For this data the null hypothesis: there is no difference between the 
drugs, is accepted. The observed level of significance is .6. 
difference 
between 
means 
(DI-DII) 
-.43 
1.43 
.12 
.01 
-.09 
-.50 
.oo 
-.60 
.47 
Table 1: Combined covariance matrix and difference between 
the means for the two drugs. 
covariance matrix 
subscale 1 2 3 4 5 6 7 J~ 
1 1.85 .66 .30 1.67 .75 .69 1.45 
2 7.34 -.98 4.12 -.20 .26 -1.58 
3 2.90 -.90 .33 .69 .77 
4 10.24 -.54 .39 -.44 
5 3.35 .39 1.74 
6 1.35 .50 
7 2.77 
8 
9 
3. Confidence intervals 
8 
.87 
.36 
-.11 
2.16 
.34 
.89 
.58 
1.90 
9 
1.09 
.73 
.79 
4.38 
-.20 
1.21 
.,67 
1.59 
5.39 
Scheffe's simultaneous confidence intervals for the difference between the 
means were computed. Because H was accepted the intervals all contain the 
0 
origin. They are included to give an idea of the precision of the experiment. 
For a description and proof of this method see Scheffe [2, pp. 68-70]. He 
there shows that the set of all points, in 9-dimensional space, that would be 
accepted as null-hypothesis for the difference between the changes produced by 
the two drugs, is an ellipsoid. He further shows that a confidence interval for 
any linear combination of the components of the difference between the group 
means can be obtained by projecting the ellipsoid onto a line defined by the 
particular linear combination. Given in Figure 2 are these projections on the 
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axes corresponding to each subscale of the Wittenborn. These confidence intervals 
are for a = .05. The half-lengths of these intervals are in the center column 
of Table 2. For comparison there are also, in Table 2, given the corresponding 
half-lengths for levels of significance a= .01 and a= .10. 
Table 2: Half-lengths of simultaneous confidence intervals for 
the difference between the drugs. 
subs~ .01 .05 .10 
1 3.0 2.5 2.3 
2 6.o 5.0 4.6 
3 3°7 3.1 2.8 
4 7.1 5.9 5.4 
5 4.o 3.4 3.1 
6 2.6 2.2 2.0 
7 3.7 3.1 2.8 
8 3.0 2.5 2.3 
9 5.1 4.3 3o9 
If the sample sizes had been doubled {to 32 and 34) the corresponding half-
lengths would be approximately ,6 times those in Table 2 for all three levels of 
significance. Had the sample sizes been quadrupled the half-lengths would be 
about .4 times those given. The comparisons assume that changes in the sample 
sizes would not produce large changes in the covariance matrices. 
4. Power of the test 
The power of Hotelling's T2 -test is given by the non-central F-distribution 
([1, p. 114] and [2, p. 418]). The non-centrality parameter is given by 
5 = , 
where N1 and N2 are the sample sizes, E is the population covariance matrix 
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Figure 2: Simultaneous confidence intervals and means for the difference between the drugs. 
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and~ is the difference between the population means; this difference 6. is a 
vector of 9 variables (the nine differences between the changes on the nine 
Wittenborn subscales} • 
The graph in Figure 3 gives the power as a function of c, where 6. is taken 
to be c times the vector of standard deviations. If the true difference be-
tween the two treatments is half of a standard deviation on each subscale!the 
power is .38 if each sample size is 15; the power is .55 if each sample size 
is 20; and the power is • 87 if each sample. size is 35. These calculations 
were made assuming that the covariance matrix observed here is the ( connnon) 
population covariance matrix; the level of significance is .05. The 
corresponding curves for a= .01 are given in Figure 4. 
5. Remark 
The null hypothesis for Hotelling's T2 is that of no difference between 
the mean vectors. It is of interest to have a test which would be insensitive 
to a difference only in magnitude of change and sensitive to difference in 
direction of change. Such a test would be more appropriate to the question: 
"Is the set of symptoms on which drug I acts different from those on which 
drug II acts?". The likelihood ratio test for H
0
: µI= aµII+b has been derived 
and will be the subject of a separate report. 
The authors wish to thank Richard Borden for the care with which he 
carried out the computations for this report. 
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Figure 3: Powe~ of Hotelling's T2 for sample sizes N1 = N2 = 15; 20 and 35 
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Figure 4: Power of Hotelling's T2 for sample sizes N = N = 15; 20 and 35 1 2 
as a function of c, where 6.= c(a1, ••• ,a9) (a= .01) 
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Data Drug l thioridazine (Mellaril) 
- Pretreatment Posttreatment 
Patient subscale subscale 
1 2 3 4 5 6 7 8 9 1 2 3 4 5 6 7 8 9 
1.1 1 6 1 1 3 1 1 1 1 2 9 1 4 6 1 1 1 1 
I.2 1 7 1 3 3 1 1 2 1 1 8 1 2 2 1 1 1 1 
1.3 1 5 1 2 4 2 1 2 3 2 5 1 1 1 1 1 1 1 
1.4 1 6 2 4 4 3 1 4 1 3 2 1 2 3 3 3 5 2 
1.5 2 5 4 2 1 1 2 1 2 2 4 1 4 1 2 1 3 4 
1.6 2 4 3 5 3 5 5 5 4 2 4 3 5 3 5 5 5 4 
I.7 1 5 1 2 2 1 1 1 1 1 4 1 3 1 1 1 2 1 
1.8 2 9 1 6 2 2 2 3 2 1 4 1 5 1 2 1 4 2 
1.9 1 6 3 8 3 2 1 3 9 1 6 1 4 4 2 1 3 2 
1.10 2 7 1 8 2 2 1 3 2 2 2 5 3 1 5 3 4 3 
1.11 3 7 1 9 4 2 4 4 9 3 4 1 6 7 3 5 4 5 
I.12 1 1 1 2 2 1 3 1 1 2 4 1 5 3 5 3 4 6 
1.13 4 9 1 6 8 1 5 3 2 3 9 1 8 3 1 1 2 1 
I.14 1 6 1 2 2 1 1. 1 1 1 3 2 1 1 1 1 1 1 
1.15 2 4 1 4 2 4 3 5 1 1 3. 1 9 1 3 3 5 5 
1.16 2 5 1 9 1 6 3 9 9 3 1 1 9 2 7 5 8 9 
... 
-
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Data Drug II carphenazine (Proketazine) 
Pretreatment Posttreatment 
Patient subscale subscale 
1 2 3 4 5 6 7 8 9 1 2 3 4 5 6 7 8 9 
II.l 1 1 1 3 3 1 1 1 2 2 6 1 2 1 2 1 1 4 
II.2 1 6 1 3 2 2 1 3 1 3 3 1 5 3 4 3 4 5 
II.3 1 3 1 2 3 1 1 2 1 1 3 1 1 1 1 1 1 1 
IIo4 3 9 1 5 5 2 5 2 2 2 9 1 7 3 2 2 4 3 
II.5 2 6 4 2 2 1 1 1 1 2 9 1 2 2 1 1 2 1 
II.6 2 6 1 4 5 1 4 4 3 1 9 1 6 2 1 1 2 2 
II.7 1 5 1 3 2 1 1 1 1 1 9 1 6 2 1 1 2 1 
II.8 3 9 4 9 1 3 2 6 3 3 9 1 8 2 2 3 6 1 
II.9 3 5 1 8 1 4 4 7 4 2 4 1 3 3 2 4 3 3 
II.10 2 9 1 8 3 1 1 3 2 3 7 7 4 6 2 4 3 2 
II.11 2 5 1 2 2 2 3 3 1 4 9 3 9 2 3 3 4 5 
IIol2 4 9 1 7 6 1 7 3 1 3 6 1 4 3 1 7 2 1 
II.13 1 4 1 1 1 1 1 1 1 3 5 1 3 1 2 3 1 2 
II.14 3 9 1 9 2 2 2 4 3 1 5 1 4 1 2 1 3 1 
IIol5 2 9 4 4 3 2 1 3 1 1 9 3 8 2 1 1 3 1 
II.16 6 9 1 9 3 2 4 5 2 1 9 1 3 2 1 1 2 1 
II.17 2 6 1 4 1 3 1 3 1 2 2 1 6 1 2 4 4 3 
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Means and Covariances Matrices 
111:1 
Drug I 
covariance matrix 
means 
subscale 
J,~ 1 2 3 4 5 6 7 8 9 
-.19 1 .70 .25 -.12 -.31 .54 023 .72 .14 .15 
1.25 2 6.47 -1.15 3.77 .63 "00 -1.45 .08 .72 
.06 3 2.06 -1.14 -.43 .63 .60 -.18 .73 
- .13 4 7.32 -.32 -.47 -1.73 044 4.79 
.38 5 3.98 .Bo 1.49 .59 -.63 
-.50 6 1.73 .50 .97 lo30 
-.06 7 2o06 .18 .14 
-.31 8 1.30 lo62 
.06 ·9 7.8o 
Drug II 
covariance matrix 
subscale 1 2 3 4 5 6 7 8 9 means J_.--? 
.24 1 2o94 L04 .70 3o53 .94 1.13 2.14 1.55 1.98 
-.18 2 8.15 -.82 4.46 
-
0 97 .50 -1.70 .62 .74 
.... 
-c,06 3 3.68 -.68 1.03 e75 .93 -.04 .85 
012 4 12.99 -.75 1.19 e76 3.78 3.99 
.47 5 2.76 .oo l.97 .10 .21 
.oo 6 1.00 .50 .81 1.13 
-.06 7 3e43 .96 lel6 
.29 8 2.47 1.57 
-.41 9 3.13 
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